‘‘The drug is an allosteric modulator that works through a mechanism that has been clinically validated in the treatment of disorders like schizophrenia.’’
6 Likes
Thank you! Looks like the muscarinic receptors might have some interesting influence on the brain. KarXT, slated for possible approval in the fall of 2024, also acts on them.
And this new one acts on the M4:
The clinical trial has been initiated by Neumora Therapeutics Inc., a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments are developed. Vanderbilt and Neumora signed an exclusive, worldwide license and a research collaboration agreement for two novel series of M4 receptor modulator compounds, including NMRA-266, in February 2022.
1 Like
It appears that the ‘‘third generation’’ antipsychotics will all be muscarinic. Let’s hope they are better than the current ones. I trust that it will be so.
3 Likes